ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Alabama » Cardiovascular Disease

Top Cardiovascular Disease Prescribers in Alabama

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
BASEL ALREFAI MD

Cardiovascular Disease

20,675

$1.19M

732
413 are 65+

3%
patients receiving schedule two controlled substances

Avg: 0%

27%
patients receiving schedule three controlled substances

Avg: 2%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

28%
prescriptions for brand name drugs

Avg: 22%

$57
Average prescription price

Avg: $57

FRANK LESTER M.D.

Cardiovascular Disease

20,456

$893K

911
784 are 65+

4%
patients receiving schedule two controlled substances

Avg: 0%

16%
patients receiving schedule three controlled substances

Avg: 2%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 22%

$44
Average prescription price

Avg: $57

IVAN SLAVICH D.O.

Cardiovascular Disease

16,759

$702K

416
189 are 65+

3%
patients receiving schedule two controlled substances

Avg: 0%

39%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

18%
prescriptions for brand name drugs

Avg: 22%

$42
Average prescription price

Avg: $57

RICKY FENNELL MD

Cardiovascular Disease

16,309

$1.07M

534
392 are 65+

5%
patients receiving schedule two controlled substances

Avg: 0%

19%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 22%

$66
Average prescription price

Avg: $57

MIR VARQUEZ M.D.

Cardiovascular Disease

15,903

$995K

1033
810 are 65+

1%
patients receiving schedule two controlled substances

Avg: 0%

5%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

28%
prescriptions for brand name drugs

Avg: 22%

$63
Average prescription price

Avg: $57

NELSON GWINN M.D.

Cardiovascular Disease

14,947

$635K

1294
1029 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

21%
prescriptions for brand name drugs

Avg: 22%

$42
Average prescription price

Avg: $57

VIKRAM ARORA MD

Cardiovascular Disease

13,531

$482K

693
570 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

17%
prescriptions for brand name drugs

Avg: 22%

$36
Average prescription price

Avg: $57

KENNETH BURNHAM MD

Cardiovascular Disease

13,322

$1.16M

1011
719 are 65+

1%
patients receiving schedule two controlled substances

Avg: 0%

3%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 22%

$87
Average prescription price

Avg: $57

KEVIN SUBLETT M.D.F.A.C.C.

Cardiovascular Disease

13,236

$947K

787
615 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

4%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 22%

$72
Average prescription price

Avg: $57

RICHARD CHERNICK MD

Cardiovascular Disease

12,277

$484K

1163
953 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

20%
prescriptions for brand name drugs

Avg: 22%

$39
Average prescription price

Avg: $57

MICHAEL AIKENS MD

Cardiovascular Disease

12,235

$1.02M

643
378 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

12%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 22%

$83
Average prescription price

Avg: $57

JOHN MCBRAYER MD

Cardiovascular Disease

12,182

$399K

767
612 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

2%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

18%
prescriptions for brand name drugs

Avg: 22%

$33
Average prescription price

Avg: $57

WILLIAM HEATON MD

Cardiovascular Disease

12,004

$671K

860
719 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 22%

$56
Average prescription price

Avg: $57

CLIFTON LATTING M.D.

Cardiovascular Disease

11,698

$402K

338
243 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

20%
patients receiving schedule three controlled substances

Avg: 2%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

19%
prescriptions for brand name drugs

Avg: 22%

$34
Average prescription price

Avg: $57

JOHN EAGAN MD

Cardiovascular Disease

11,574

$620K

848
688 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

2%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

28%
prescriptions for brand name drugs

Avg: 22%

$54
Average prescription price

Avg: $57

CHRISTOPHER CENTAFONT D.O.

Cardiovascular Disease

11,524

$441K

870
662 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 22%

$38
Average prescription price

Avg: $57

GLENN COCHRAN MD

Cardiovascular Disease

11,199

$429K

1149
934 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

3%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

17%
prescriptions for brand name drugs

Avg: 22%

$38
Average prescription price

Avg: $57

ALAIN BOUCHARD MD

Cardiovascular Disease

11,112

$587K

776
578 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

2%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 22%

$53
Average prescription price

Avg: $57

WILLIAM HARRISON MD

Cardiovascular Disease

11,086

$503K

676
586 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

2%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 22%

$45
Average prescription price

Avg: $57

MICHAEL WILENSKY MD

Cardiovascular Disease

10,915

$593K

864
721 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 22%

$54
Average prescription price

Avg: $57

CHRISTOPHER BYARD M.D.

Cardiovascular Disease

10,568

$492K

735
617 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

2%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 22%

$47
Average prescription price

Avg: $57

JAMES LEE M.D.

Cardiovascular Disease

10,342

$375K

722
541 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

18%
prescriptions for brand name drugs

Avg: 22%

$36
Average prescription price

Avg: $57

DARIUS ALIABADI M.D.

Cardiovascular Disease

10,269

$562K

989
739 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

2%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

29%
prescriptions for brand name drugs

Avg: 22%

$55
Average prescription price

Avg: $57

PHILLIP LANEY M.D.

Cardiovascular Disease

10,153

$561K

746
633 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 22%

$55
Average prescription price

Avg: $57

RUSSELL REEVES MD

Cardiovascular Disease

10,088

$387K

633
520 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

5%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

18%
prescriptions for brand name drugs

Avg: 22%

$38
Average prescription price

Avg: $57

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank